11.10.16
Mylan
3Q Revenues: $3.1 billion (+13%)
3Q Loss: $119.8 million (earnings were $428.6 million 3Q15)
YTD Revenues: $7.8 billion (+13%)
YTD Earnings: $62.5 million (earnings were $653.1 million YTD15)
Comments: Generics segment third party sales in the quarter were $2.6 billion, up 17%. Specialty segment sales were $418.7 million, down 4%. Loss in the quarter was primarily a result of the company’s $465 million settlement with the U.S. Department of Justice and other government agencies related to the classification of the EpiPen for purposes of the Medicaid Drug Rebate Program.
3Q Revenues: $3.1 billion (+13%)
3Q Loss: $119.8 million (earnings were $428.6 million 3Q15)
YTD Revenues: $7.8 billion (+13%)
YTD Earnings: $62.5 million (earnings were $653.1 million YTD15)
Comments: Generics segment third party sales in the quarter were $2.6 billion, up 17%. Specialty segment sales were $418.7 million, down 4%. Loss in the quarter was primarily a result of the company’s $465 million settlement with the U.S. Department of Justice and other government agencies related to the classification of the EpiPen for purposes of the Medicaid Drug Rebate Program.
